Selank
Selank is a tuftsin-related neuropeptide discussed around GABAergic, stress-response, and regional anxiolytic research context.
- Evidence level
- Early human data
- Human studies
- 1
- Total sources
- 5
- Last reviewed
- 2026-06-03
Reviewed by Bryan Powell · editorial review, not medical review
tuftsin analog biology · GABAergic signaling · stress response
At a glance
Selank is a neuropeptide topic that requires careful language because anxiety and stress-resilience claims can become medical claims quickly. The best public profile explains tuftsin-related biology, GABAergic and neuroimmune discussion, Russian clinical context, and why psychiatric treatment claims do not belong in this library.
What Selank is
Selank is a synthetic heptapeptide related to tuftsin biology, commonly discussed around anxiolytic research, GABAergic neurotransmission, neuroimmune signaling, and stress response. It has regional clinical literature, but that should not be treated as broad Western validation. The entry should help readers understand why it is discussed without giving personal psychiatric guidance.
Mechanism
Why It Shows Up in Stress and Neuroimmune Discussions
The biological context centers on tuftsin-related peptide biology, GABAergic signaling, stress-response systems, neuroimmune modulation, and cognitive-stress discussion. Those themes are relevant to resilience education, but they are also medically adjacent. Public content should stay educational and avoid claims that Selank treats anxiety or psychiatric conditions.
Tuftsin-Related Biology, Without Treatment Claims
Selank is discussed mechanistically through molecular reviews of heptapeptide biological activity, including GABAergic and regulatory-peptide context. Preclinical gene-expression work supports discussion of neurotransmission and stress-model biology. Those mechanisms can explain research interest without proving broad outcomes.
Human literature exists in regional anxiety-spectrum contexts, but it should be handled as limited and geographically specific. Aeternus can acknowledge that evidence without presenting Selank as a psychiatric treatment, a stress solution, or a cognitive enhancer.
What the evidence actually shows
Human data
Direct human trial evidence among the reviewed sources.
Preclinical data
Animal or in-vitro work. Does not establish human effect.
Anecdotal discussion
Reported experience. Not evidence of effect.
Where people overreach
Regional clinical evidence is limited. Russian studies should be interpreted by design, population, language, and regulatory context.
Anxiolytic discussion can become a treatment claim. Public content must avoid suggesting psychiatric care or self-treatment.
Preclinical stress models do not equal human stress resilience. Mechanism should stay separate from outcome.
Western regulatory status remains limited. The entry should not imply FDA or EMA approval.
Safety and regulatory context
Mental-health context matters. Public content should not encourage unsupervised use for anxiety, mood, stress, or psychiatric symptoms.
Regulatory status matters. Regional clinical use does not equal broad international approval.
Product identity matters. Research materials and clinical products may differ in quality, oversight, and evidence relevance.
Practical interpretation
Selank appears in performance discussions because stress regulation, emotional control, and cognitive resilience are attractive themes. Those themes are also easy to overstate. Aeternus frames Selank as a neuroimmune and stress-response research topic, not as an anxiety or productivity solution.
The practical interpretation should separate research context from personal use. Selank can be discussed through tuftsin-related biology, regional clinical literature, and preclinical stress models. It should not be framed as a substitute for qualified mental-health care or as an unsupervised stress-management strategy.
The reader should leave with a clearer map of evidence, not with a suggested action. Regional human literature, molecular reviews, gene-expression studies, and anecdotal discussion each answer different questions. Keeping those categories separate prevents a medically adjacent topic from becoming a disguised recommendation.
What Selank is not
Not an anxiety-treatment claim. Selank should not be framed as treating, curing, or preventing psychiatric conditions.
Not a guaranteed calm or focus tool. Stress-response biology does not prove predictable cognitive or emotional outcomes.
Not a Western-approved medicine. Regional context should be described carefully.
Aeternus position
Aeternus views Selank as a medically adjacent neuropeptide topic where caution is essential. The biology and regional evidence are worth explaining, but public language must avoid psychiatric treatment claims. The right position is calm, precise education: describe tuftsin-related and GABAergic context, note the evidence limits, and keep safety and regulatory boundaries visible.
Regulatory status
Three separate questions, kept separate on purpose. Whether Selank appears on FDA’s pharmacy-compounding list, whether an approved medicine containing it exists, and whether it is banned in sport are three different things, and the answer to one tells you nothing about the others.
FDA 503A bulk substances list
On neither list
Does not appear on FDA’s Category 1 or Category 2 bulk substances lists.
Left FDA Category 2 on or about 2026-04-22 because the nominators withdrew the nomination, not because FDA resolved its safety concerns. Those concerns remain published. FDA lists it as 'Selank acetate (TP-7)'. Not on the July 2026 PCAC agenda.
Primary sourceSource directness: high — a named primary document states this outright
FDA approval
No FDA-approved product
Primary sourceSource directness: high — a named primary document states this outright
WADA prohibited list
Could not verify · captured by class wording, not named
Not named on the Prohibited List. Same unresolved question as Semax: S0 turns on non-US approval status we could not verify from a primary registry.
Primary sourceSource directness: low — the sources permit more than one careful reading
Verified against primary sources on 2026-07-31 · last regulatory change 2026-04-22
Regulatory status changes, sometimes quickly. This reflects what the primary sources said on the date above and nothing more. Verify before acting on it.
Sources (5)
- review · moderatePeptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological ActivityProtein and Peptide Letters, 2018 · doi:10.2174/0929866525666180925144642
- human study · limitedOptimization of the treatment of anxiety disorders with selankZhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015 · doi:10.17116/jnevro20151156133-40
- preclinical · limitedSelank Administration Affects the Expression of Some Genes Involved in GABAergic NeurotransmissionFrontiers in pharmacology, 2016 · doi:10.3389/fphar.2016.00031
- animal study · limitedPeptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in RatsBehavioural neurology, 2017 · doi:10.1155/2017/5091027
- regulatory · limitedThe Prohibited ListWADA, 2026
Aeternus Performance provides educational content only. This page summarizes available research and common discussion points around this compound. It is not medical advice, does not diagnose, treat, cure, or prevent disease, and should not be used as a substitute for guidance from a qualified medical professional.